Ardelyx, Inc. filings document a commercial-stage biopharmaceutical company with U.S. product revenue from IBSRELA and XPHOZAH and development activity centered on tenapanor and NHE3 inhibition. Form 8-K reports cover quarterly operating results, preliminary product sales, cash and investment updates, Regulation FD presentation materials, and other material-event disclosures tied to the company’s commercial and clinical programs.
Ardelyx proxy materials describe annual meeting proposals, director elections, say-on-pay matters, auditor ratification, executive compensation, board structure, and stockholder voting mechanics. Additional current reports record officer appointments, executive transitions, transition and separation agreements, compensatory arrangements, governance matters, and disclosure controls relevant to the company’s public-company reporting obligations.
ARDELYX, INC. Chief Financial Officer Susan Hohenleitner reported an automatic tax-related sale of company stock. On February 20, 2026, she sold a total of 2,033 shares of common stock in open-market transactions, at prices of $5.865 and $5.7138 per share. According to a footnote, these sales were an automatic sell-to-cover triggered by vesting restricted stock units and were made solely to cover withholding taxes. After these transactions, she directly owned 230,533 shares of Ardelyx common stock.
Ardelyx, Inc. executive Brady James Parker, the Chief Human Resources Officer, reported selling a total of 2,543 shares of common stock on February 20, 2026 in open-market transactions at prices of $5.865 and $5.7138 per share.
According to the footnote, these sales were an automatic sell-to-cover triggered upon the vesting of restricted stock units and were executed solely to cover applicable withholding taxes. After the transactions, Parker directly owned 262,912 Ardelyx shares.
Ardelyx, Inc. officer Mike Kelliher reported automatic sales of company common stock tied to vested restricted stock units. On February 20, 2026, he sold a total of 9,595 shares in open-market transactions at prices around $5.71–$5.87 per share.
According to the footnote, these were “automatic sell-to-cover” transactions required under the original RSU grant terms and were executed solely to cover withholding taxes, rather than discretionary sales. After these transactions, Kelliher directly holds 364,666 shares of Ardelyx common stock.
ARDELYX, INC. President & CEO Michael Raab reported open-market sales of a total of 45,982 shares of common stock on February 20, 2026, at prices around $5.70 to $5.87 per share. According to the filing, these sales were executed pursuant to an automatic sell-to-cover feature tied to restricted stock unit vesting and were made solely to cover applicable withholding taxes.
After these transactions, Raab directly holds 1,856,988 shares as trustee of the Michael G. Raab Living Trust dated July 25, 2012, and also has indirect ownership of 24,364 and 1,000 shares through trusts established for his children.
Ardelyx, Inc. Chief Commercial Officer Eric Duane Foster reported open-market sales of a total of 10,439 shares of common stock on February 20, 2026, at prices between $5.7003 and $5.865 per share. According to the footnote, these trades were executed automatically to sell shares upon restricted stock unit vesting solely to cover withholding taxes. After these transactions, he directly owned 425,970 Ardelyx common shares.
Ardelyx, Inc. officer Joseph James Reilly amended a notice to sell 4,991 shares of common stock, with an aggregate market value of $33,539.52 and an approximate sale date of February 20, 2026. The amendment increases the share amount by 91 because the automated tax-withholding sale executed at a lower-than-expected price. The shares came from vesting of 10,388 restricted stock units on February 19, 2026; the automatic sell-to-cover is imposed by the award terms and is solely to cover applicable withholding taxes. The notice reports 245,247,427 common shares outstanding. Reilly also reported a sale of 11,086 shares for gross proceeds of $61,382.07 on November 21, 2025.
Laura A. Williams, an officer of ARDELYX, INC., reported a planned sale of 11,300 common shares, with an aggregate market value of $64,749 and an approximate sale date of February 20, 2026. The shares were acquired through the vesting of 24,041 restricted stock units on February 19, 2026. Under the awards’ automatic sell-to-cover terms, shares are to be sold upon vesting solely to cover applicable withholding taxes.
ARDX submitted a Form 144 reporting proposed sales of Common Stock. The filing lists 11,800 shares, notes 24,986 shares tied to the vesting of restricted stock units on 02/19/2026, and discloses a prior sale of 5,560 shares on 11/21/2025.
ARDELYX, INC. officer Joseph James Reilly reported a proposed sale of 4,900 common shares, with an approximate sale date of February 20, 2026 and an aggregate market value of $28,077.00. The shares were acquired through vesting of 10,388 restricted stock units on February 19, 2026. The sale is described as an automatic sell-to-cover under the initial award terms, solely to cover applicable withholding taxes.
Ardelyx, Inc. (ARDX) officer Eric Duane Foster reported plans to sell 13,350 common shares, with an aggregate market value of $76,495.50 and an approximate sale date of February 20, 2026. The shares are to be sold upon restricted stock unit vesting solely to cover applicable withholding taxes under an automatic sell-to-cover arrangement; Foster acquired 28,415 common shares through vesting on February 19, 2026, in exchange for services rendered.